文献速递帕金森病与运动障碍认知障碍与痴呆

REM睡眠行为障碍中的神经保护试验:前进之路愈发清晰

Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer.
PubMed 文献 · Neurology · 2022-01-01

本文综述了特发性/孤立性REM睡眠行为障碍(iRBD)作为前驱期帕金森病/路易体痴呆神经保护试验人群的潜力,指出iRBD是现有唯一大型未治疗的前驱期队列,超过80%的患者会发展为完全神经退行性突触核蛋白病,并讨论了病理生理机制、入选标准和最佳主要结局指标。

要点

  • iRBD患者是现有唯一大型未治疗的前驱期帕金森病/路易体痴呆队列,可立即启动临床试验。
  • 目前有数千名RBD患者在研究型诊所随访,其中超过80%将发展为完全神经退行性突触核蛋白病。
  • RBD表型转化率和预测因素研究进展显著,可生成更精确的进展率估计并选择分层标志物富集试验。

核心结论

  • iRBD患者是现有唯一大型未治疗的前驱期帕金森病/路易体痴呆队列,适合立即启动神经保护试验。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 目前有数千名RBD患者在研究型诊所随访,其中超过80%将发展为完全神经退行性突触核蛋白病。
  • RBD表型转化率和预测因素研究进展显著,可生成更精确的进展率估计并选择分层标志物富集试验。
  • 已能理解不同主要结局指标对进展和样本量的影响。

关键数值与推荐

  • 原文未报告具体入选标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As neuroprotective therapies continue to be advanced against neurodegenerative synucleinopathies, such as Parkinson disease (PD), dementia with Lewy bodies (DLBs), and multiple system atrophy, increasing attention is turning to the prodromal stages of disease. Treatments at the prodromal stage have the compelling advantages of being applied early enough to make a meaningful difference and can be tested without confounding by symptomatic therapies used for clinical PD/DLB. As it currently stands, patients with idiopathic/isolated REM sleep behavior disorder (iRBD) represent the only large existing cohort of untreated prodromal PD/DLB that would be ready to start a clinical trial now. Several thousand patients with RBD are currently being followed in research-based clinics, and more than 80% of them will develop a full neurodegenerative synucleinopathy. Research into RBD phenoconversion rates and predictors has advanced considerably, and we are now able to generate increasingly precise estimates of progression rates, can select stratification markers to enrich trials, and are able to understand the progression and sample size implications of different primary outcome measures. This review will outline the potential for neuroprotective trials in iRBD, including the pathophysiologic mechanisms with the most promise to target in iRBD, selection criteria for inclusion, and the optimal primary trial outcome measures to choose.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Postuma RB. Neuroprotective Trials in REM Sleep Behavior Disorder: The Way Forward Becomes Clearer. Neurology. 2022. PMID: 35970587. doi:10.1212/WNL.0000000000200235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。